Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Satoki Fujita"'
Autor:
Takahiro Takazono, Satoki Fujita, Takuji Komeda, Shogo Miyazawa, Yuki Yoshida, Yoshitake Kitanishi, Masahiro Kinoshita, Satoshi Kojima, Huilian Shen, Takeki Uehara, Naoki Hosogaya, Naoki Iwanaga, Hiroshi Mukae
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 8, Pp 1821-1833 (2024)
Abstract Introduction This study aimed to evaluate the effectiveness of ensitrelvir, an oral antiviral, in reducing hospitalization risk in outpatients at high-risk for severe COVID-19 during the Omicron era. Methods This was a retrospective study us
Externí odkaz:
https://doaj.org/article/7413e1399c5245c6a312d602e8452527
Autor:
Genta Ito, Takahiro Takazono, Naoki Hosogaya, Naoki Iwanaga, Shogo Miyazawa, Satoki Fujita, Hideaki Watanabe, Hiroshi Mukae
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Factors affecting the start date of the influenza epidemic season and total number of infected persons per 1,000,000 population in 47 prefectures of Japan were evaluated. This retrospective observational study (September 2014–August 2019;
Externí odkaz:
https://doaj.org/article/95cc4b0e328c40a49d22eca386a126e0
Publikováno v:
Japanese Journal of Statistics and Data Science. 5:339-361
This study proposes a direction for the utilization of multi-agent simulation (MAS) to consider an optimal prevention strategy for the spread of the coronavirus disease of 2019 (COVID-19) through a pandemic modeling example in Japan. MAS can flexibly
Autor:
Shogo Miyazawa, Takahiro Takazono, Naoki Hosogaya, Kazuko Yamamoto, Hideaki Watanabe, Masakazu Fujiwara, Satoki Fujita, Hiroshi Mukae
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 75(6)
Background: Influenza affects approximately a billion people globally, including > 10 million Japanese individuals every year. Baloxavir marboxil (baloxavir [BXM]; a selective cap-dependent endonuclease inhibitor) is approved for influenza treatment